Safety and Effectiveness of Rivaroxaban Versus Warfarin Across GFR Levels in Atrial Fibrillation: A Population-Based Study in Australia and Canada
Authors:
Open Access
- 17 May 2023
- journal article
- research article
- Published by Elsevier in Kidney Medicine
- Vol. 5 (7) , 100675
Abstract
No abstract availableKeywords
Funding Information
- Amgen
- University of New South Wales
- University of British Columbia
- Ministry of Health -Singapore
- AstraZeneca
- Institute for Clinical Evaluative Sciences
- Canadian Institutes of Health Research
- National Health and Medical Research Council (1148060)
This publication has 30 references indexed in Scilit:
- A systematic review of validated methods for identifying atrial fibrillation using administrative dataPharmacoepidemiology and Drug Safety, 2012
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine, 2011
- Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairmentEuropean Heart Journal, 2011
- An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational StudiesMultivariate Behavioral Research, 2011
- Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitorBritish Journal of Clinical Pharmacology, 2010
- Impact of Proteinuria and Glomerular Filtration Rate on Risk of Thromboembolism in Atrial FibrillationCirculation, 2009
- Accuracy of coding for possible warfarin complications in hospital discharge abstractsThrombosis Research, 2006
- A comparison of propensity score methods: a case‐study estimating the effectiveness of post‐AMI statin useStatistics in Medicine, 2005
- Coding of Stroke and Stroke Risk Factors Using International Classification of Diseases , Revisions 9 and 10Stroke, 2005
- Measuring inconsistency in meta-analysesBMJ, 2003